We are live on ! Find out more
PA

Profund Advisors Portfolio holdings

AUM $3.64B
1-Year Est. Return 83.38%
This Fund
S&P 500
This Quarter Est. Return
+49.74%
1 Year Est. Return
+83.38%
3 Year Est. Return
+239.61%
5 Year Est. Return
+330.19%
10 Year Est. Return
+1,383.86%
AUM
$3.64B
AUM Growth
+$913M
Cap. Flow
+$245M
Cap. Flow %
6.73%
Top 10 Hldgs %
40.93%
Holding
1,250
New
158
Increased
429
Reduced
585
Closed
75

Top Buys

Rank Stock Value
1
NVDA icon
NVIDIA
NVDA
+$72.2M
2
AVGO icon
Broadcom
AVGO
+$27.9M
3
SNDK
Sandisk
SNDK
+$15M
4
AAPL icon
Apple
AAPL
+$13.9M
5
MU icon
Micron Technology
MU
+$12.9M

Sector Composition

Rank Sector Weight
1 Technology 56.05%
2 Healthcare 8.58%
3 Communication Services 8.31%
4 Consumer Discretionary 7.81%
5 Industrials 3.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
PFE icon
226
Pfizer
PFE
$162B
$1.77M 0.05%
73,381
+1,354
+2% +$35.4K
ABT icon
227
Abbott
ABT
$187B
$1.76M 0.05%
19,402
-31
-0.2% -$2.83K
EQT icon
228
EQT Corp
EQT
$34.5B
$1.76M 0.05%
33,045
+3,524
+12% +$198K
DELL icon
229
Dell
DELL
$339B
$1.75M 0.05%
4,058
+494
+14% +$143K
RVMD icon
230
Revolution Medicines
RVMD
$45B
$1.74M 0.05%
9,317
-10,424
-53% -$1.52M
TVTX icon
231
Travere Therapeutics
TVTX
$6.15B
$1.74M 0.05%
30,574
-37,344
-55% -$1.66M
CDE icon
232
Coeur Mining
CDE
$21.8B
$1.73M 0.05%
105,893
-24,337
-19% -$444K
SYRE icon
233
Spyre Therapeutics
SYRE
$7.85B
$1.72M 0.05%
19,419
-6,624
-25% -$483K
PBR.A icon
234
Petrobras Class A
PBR.A
$118B
$1.72M 0.05%
117,569
-27,628
-19% -$487K
WELL icon
235
Welltower
WELL
$170B
$1.72M 0.05%
7,576
+92
+1% +$19.4K
RARE icon
236
Ultragenyx Pharmaceutical
RARE
$1.51B
$1.72M 0.05%
51,450
-20,658
-29% -$513K
HALO icon
237
Halozyme
HALO
$12.5B
$1.7M 0.05%
21,747
-10,768
-33% -$734K
EXEL icon
238
Exelixis
EXEL
$14.6B
$1.7M 0.05%
31,254
-22,328
-42% -$1.09M
NTRA icon
239
Natera
NTRA
$47.3B
$1.68M 0.05%
6,205
-3,795
-38% -$809K
CELC icon
240
Celcuity
CELC
$4.68B
$1.68M 0.05%
16,012
-1,598
-9% -$184K
INCY icon
241
Incyte
INCY
$25.7B
$1.67M 0.05%
14,722
-8,021
-35% -$795K
RGLD icon
242
Royal Gold
RGLD
$22.2B
$1.66M 0.05%
8,339
-2,455
-23% -$571K
RLAY icon
243
Relay Therapeutics
RLAY
$4.17B
$1.65M 0.05%
88,371
+20,201
+30% +$293K
ETR icon
244
Entergy
ETR
$51.3B
$1.65M 0.05%
14,335
-1,098
-7% -$124K
STLD icon
245
Steel Dynamics
STLD
$34.7B
$1.64M 0.05%
7,138
+3,201
+81% +$750K
BEAM icon
246
Beam Therapeutics
BEAM
$3.06B
$1.63M 0.04%
47,584
-29,511
-38% -$891K
PBR icon
247
Petrobras
PBR
$130B
$1.61M 0.04%
99,796
-22,673
-19% -$443K
VST icon
248
Vistra
VST
$50.1B
$1.61M 0.04%
10,127
-941
-9% -$146K
ETN icon
249
Eaton
ETN
$160B
$1.6M 0.04%
3,763
+110
+3% +$44.4K
BMRN icon
250
BioMarin Pharmaceuticals
BMRN
$12.9B
$1.6M 0.04%
27,966
-8,868
-24% -$486K

Similar funds

Profund Advisors's Q2 2026 Portfolio in Review

As of Q2 2026, Profund Advisors held 1,250 positions worth $3.64B, up 34% from $2.72B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Profund Advisors deployed $245M of net new capital in Q2 2026, opening 158 new positions and adding to 429 existing holdings. Its largest new stake was Honeywell Aerospace: 24,902 shares worth $5.51M.

By sector, the portfolio is most concentrated in Technology at 56% of assets, up from 43% a quarter earlier, followed by Healthcare and Communication Services.

On the sell side, the largest reduction was Honeywell, an estimated $5.34M trimmed.

  • Profund Advisors's largest Q2 2026 buy was Honeywell Aerospace: 24,902 shares worth $5.51M.
  • Profund Advisors added most to NVIDIA in Q2 2026, an estimated $72.2M increase.
  • Profund Advisors's biggest Q2 2026 reduction was Honeywell, cutting an estimated $5.34M.
  • Profund Advisors fully exited Apellis Pharmaceuticals in Q2 2026, selling an estimated $3.27M.
  • Profund Advisors's ten largest holdings make up 41% of its $3.64B portfolio in Q2 2026.
  • Profund Advisors opened 158 new positions and closed 75 in Q2 2026.
  • Profund Advisors's portfolio value rose 34% quarter-over-quarter to $3.64B.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.